{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:24:50Z","timestamp":1783329890040,"version":"3.54.6"},"reference-count":32,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Science and Technology Support Program of Guizhou Province","award":["[2025]373"],"award-info":[{"award-number":["[2025]373"]}]},{"name":"Science and Technology Support Program of Guizhou Province","award":["[2023]506"],"award-info":[{"award-number":["[2023]506"]}]},{"name":"Science and Technology Support Program of Guizhou Province","award":["[2023]504"],"award-info":[{"award-number":["[2023]504"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Difelikefalin, a peripherally acting selective \u03ba-opioid receptor agonist, is approved for treating chronic kidney disease-associated pruritus in adults on hemodialysis. However, real-world data on its adverse drug events (ADEs) remain limited. This study aimed to systematically identify ADE signals associated with difelikefalin in hemodialysis patients using the FDA Adverse Event Reporting System (FAERS) database, to generate hypotheses for subsequent clinical validation and provide targeted evidence for safe clinical application of difelikefalin in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ADE reports related to difelikefalin were extracted from the FAERS database (2022\u20132025). Drug names were standardized using Medex UIMA software, and ADEs were coded according to the Medical Dictionary for Regulatory Activities. Disproportionality analyses, including the reporting odds ratio (ROR) and proportional reporting ratio, were employed to detect ADE signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 328 difelikefalin-related ADE reports were included, which is limited by the relatively recent approval and limited real-world use of this agent. Demographically, male patients (49.09%) outnumbered females (24.09%), and the vast majority of patients with clear age data were aged 65 years or older. Clinically, the most frequent outcomes were \u201cother serious\u201d events (46.01%), hospitalization (33.46%), and death (15.59%). At the System Organ Class level, \u201cNervous system disorders\u201d (ROR\u00a0=\u00a03.4) and \u201cPsychiatric disorders\u201d (ROR\u00a0=\u00a02.99) showed the strongest ADE signals. At the Preferred Term level, high-risk signals included mental status changes (ROR\u00a0=\u00a085.65), disorientation (ROR\u00a0=\u00a033.62), electric shock sensation (ROR\u00a0=\u00a032.09), somnolence (ROR\u00a0=\u00a016.25), fall (ROR\u00a0=\u00a08.46), and fracture (ROR\u00a0=\u00a021.06). We also identified several rare ADE signals unreported in Phase III clinical trials (e.g. electric shock sensation and disorientation) with significant disproportional reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pharmacovigilance study identifies potential neuropsychiatric safety signals associated with difelikefalin, with a particularly elevated risk in elderly patients. These findings identify elderly hemodialysis patients as the high-risk group for difelikefalin-related ADEs, and suggest the need for targeted clinical monitoring strategies for this population; all signals require prospective cohort studies to validate potential causal relationships.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag144","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:40:48Z","timestamp":1781955648000},"source":"Crossref","is-referenced-by-count":0,"title":["Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database"],"prefix":"10.1093","author":[{"given":"Jinshan","family":"Zhao","sequence":"first","affiliation":[{"name":"The First Clinical Institute, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyu","family":"Qiu","sequence":"additional","affiliation":[{"name":"The First Clinical Institute, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8566-0448","authenticated-orcid":false,"given":"Jun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026070605020683800_bib1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/IJNRD.S499798","article-title":"Identification and management of CKD-associated pruritus: current insights","volume":"17","author":"Skrzypczak","year":"2024","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026070605020683800_bib2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2026070605020683800_bib3","doi-asserted-by":"publisher","first-page":"100458","DOI":"10.1016\/j.xkme.2022.100458","article-title":"Insomnia and poor sleep in CKD: a systematic review and meta-analysis","volume":"4","author":"Tan","year":"2022","journal-title":"Kidney Med"},{"key":"2026070605020683800_bib4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/IJNRD.S294147","article-title":"Obstacles to early diagnosis and treatment of pruritus in patients with chronic kidney disease: current perspectives","volume":"15","author":"Jha","year":"2022","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026070605020683800_bib5","doi-asserted-by":"publisher","first-page":"e0072","DOI":"10.1097\/itx.0000000000000072","article-title":"Kappa opioid agonists in the treatment of itch: just scratching the surface?","volume":"8","author":"Beck","year":"2023","journal-title":"Itch (Phila)"},{"key":"2026070605020683800_bib6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/10600280221115889","article-title":"Difelikefalin: a new \u03ba-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease\u2013associated pruritus","volume":"57","author":"Fugal","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2026070605020683800_bib7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/17512433.2023.2197209","article-title":"Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis","volume":"16","author":"Rastogi","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026070605020683800_bib8","doi-asserted-by":"publisher","first-page":"100519","DOI":"10.1016\/j.xkme.2022.100519","article-title":"Difelikefalin: a novel therapy for dialysis patient care","volume":"4","author":"Watnick","year":"2022","journal-title":"Kidney Med"},{"key":"2026070605020683800_bib9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"2026070605020683800_bib10","doi-asserted-by":"publisher","first-page":"11235","DOI":"10.3389\/jpps.2023.11235","article-title":"Gastrointestinal perforation associated with novel antineoplastic agents: a real-world study based on the FDA Adverse Event Reporting System","volume":"26","author":"Yu","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"2026070605020683800_bib11","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026070605020683800_bib12","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026070605020683800_bib13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026070605020683800_bib14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026070605020683800_bib15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2026070605020683800_bib16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Statistician"},{"key":"2026070605020683800_bib17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2018030296","article-title":"Sex-related disparities in CKD progression","volume":"30","author":"Ricardo","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026070605020683800_bib18","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/ndt\/gfaa095","article-title":"Renal function decline in older men and women with advanced chronic kidney disease\u2014results from the EQUAL study","volume":"36","author":"Chesnaye","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026070605020683800_bib19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12882-020-02151-7","article-title":"The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis","volume":"21","author":"Weldegiorgis","year":"2020","journal-title":"BMC Nephrol"},{"key":"2026070605020683800_bib20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10157-024-02570-y","article-title":"Estimating the prevalence of chronic kidney disease in the older population using health screening data in Japan","volume":"29","author":"Kobayashi","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"2026070605020683800_bib21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12882-023-03271-6","article-title":"Epidemiological analysis of death among patients on maintenance hemodialysis: results from the Beijing blood purification quality control and improvement center","volume":"24","author":"Liu","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026070605020683800_bib22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa2210699","article-title":"Phase 2 trial of difelikefalin in Notalgia paresthetica","volume":"388","author":"Kim","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070605020683800_bib23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/alz.12009","article-title":"Late-life cognitive decline is associated with hippocampal volume, above and beyond its associations with traditional neuropathologic indices","volume":"16","author":"Dawe","year":"2020","journal-title":"Alzheimers Dementia"},{"key":"2026070605020683800_bib24","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1038\/s41380-023-02226-5","article-title":"Dynorphin \/kappa-opioid receptor regulation of excitation-inhibition balance toggles afferent control of prefrontal cortical circuits in a pathway-specific manner","volume":"28","author":"Yarur","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026070605020683800_bib25","doi-asserted-by":"publisher","first-page":"106470","DOI":"10.1016\/j.phrs.2022.106470","article-title":"Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway","volume":"185","author":"Meariman","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026070605020683800_bib26","doi-asserted-by":"publisher","first-page":"100512","DOI":"10.1016\/j.xkme.2022.100512","article-title":"Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 Phase 3 studies","volume":"4","author":"Topf","year":"2022","journal-title":"Kidney Med"},{"key":"2026070605020683800_bib27","doi-asserted-by":"crossref","first-page":"1476587","DOI":"10.3389\/fphar.2024.1476587","article-title":"Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis","volume":"15","author":"Cai","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070605020683800_bib28","doi-asserted-by":"publisher","first-page":"sfaf297","DOI":"10.1093\/ckj\/sfaf297","article-title":"Real-world safety of difelikefalin for chronic kidney disease-associated pruritus: initial insights from a European managed access programme","volume":"18","author":"Latus","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026070605020683800_bib29","doi-asserted-by":"crossref","first-page":"5559981","DOI":"10.1155\/2021\/5559981","article-title":"Potential adverse consequences of combination therapy with gabapentin and pregabalin","volume":"2021","author":"Ghayur","year":"2021","journal-title":"Case Rep Med"},{"key":"2026070605020683800_bib30","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/JPR.S473226","article-title":"Gabapentinoids-related delirium adverse events: a real-world study from 2004 to 2022 based on FAERS","volume":"17","author":"Nie","year":"2024","journal-title":"J Pain Res"},{"key":"2026070605020683800_bib31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41100-017-0133-8","article-title":"Nalfurafine hydrochloride for refractory pruritus in peritoneal dialysis patients: a phase III, multi-institutional, non-controlled, open-label trial","volume":"3","author":"Nakamoto","year":"2017","journal-title":"Ren Replace Ther"},{"key":"2026070605020683800_bib32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/alcalc\/agab045","article-title":"Safety and persistence of nalmefene treatment for alcohol dependence. Results from two post-authorisation safety studies","volume":"56","author":"Chick","year":"2021","journal-title":"Alcohol Alcohol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag144\/68576221\/gfag144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag144\/68576221\/gfag144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:02:23Z","timestamp":1783328543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag144\/8713284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag144","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"gfag144"}}